Symptoms and the distress they cause: Comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension

Archives of Internal Medicine

Volumn 163, Issue 13, 2003, Pages 1543-1548

  Hollenberg, Norman K ^a   Williams, Gordon H ^a   Anderson, Richard ^b   Akhras, Kasem S ^c   Bittman, Richard M ^c   Krause, Scott L ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CoMMensa Inc ^*  (United States)

^c Pharmacia Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; EPLERENONE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FEMALE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; VALIDATION PROCESS;

NON-PROGRAMMATIC;

AGED; ALDOSTERONE ANTAGONISTS; AMLODIPINE; ANALYSIS OF VARIANCE; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; QUALITY OF LIFE; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0037817776     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.13.1543     Document Type: Article

References (23)

1. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
2. Coats AJS. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA). Int J Cardiol. 2001;80:1-4.
3. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001;94:378-383.
4. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep. 2001;3:240-248.
5. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345: 1689-1697.
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-585.
7. Karim A. Spironolactone: deposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978;8:151,
8. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther. 1979;25:33.
9. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. JAMA. 1973;225:40.
10. Hollenberg NK, Williams GH, Anderson R. Medical therapy, symptoms, and the distress they cause: relation to quality of life in patients with angina pectoris and/or hypertension. Arch Intern Med. 2000;160:1477-1483.
11. Anderson RB, Hollenberg NK, Williams GH. Physical symptoms distress index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med. 1999;159:693-700.
12. Meinert CL. Patient follow-up, close-out, and post-trial follow-up. In: Meinert CL, Tonascia S, eds. Clinical Trials: Design, Conduct, and Analysis. Vol 8. New York, NY: Oxford University Press; 1986:159-165.
13. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
14. Schoenberger JA, Croog SH, Sudilovsky A, Levine S, Baume RM. Self-reported side effects from antihypertensive drugs: a clinical trial. Am J Hypertens. 1990; 3:123-132.
15. Anderson RB, Testa MA. Symptom distress checklists as a component of quality of life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via he physician. Drug Inf J. 1994;28: 898-114.
16. Testa MA, Anderson RB, Nackley JF, Hollenberg NK, and the Quality-of-Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Engl J Med. 1993;328:907-913.
17. Cantril H, ed. The Pattern of Human Concerns. New Brunswick, NJ: Rutgers University Press; 1965:1-427.
18. Stewart AL. The Medical Outcomes Study framework of health indicators. In: Stewart A, Ware JE, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:12-24.
19. Cote LJ, Gleser LJ, Gupta S, Puri P, Samuels S, eds. KC Sreedharan Pillai 1920-1985, Advances in Multivariate Statistical Analysis. Boston, Mass: Reidel Publishing; 1987.
20. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087.
21. Norusis M. SPSS Advanced Statistics User's Guide. Chicago, III: SPSS Inc; 1990: 94-95.
22. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619-625.
23. Ware JE. Methodological considerations in the selection of health status assessment procedures. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York, NY: Le Jacq Publishing; 1984:87-117.